ASH Clinical News provides daily news and updates from the hematology/oncology community. Here are some highlights of this week’s coverage: |
|
FDA Committee Supports Gemtuzumab Ozogamicin for Acute Myeloid Leukemia The Oncologic Drugs Advisory Committee voted 6-1 in support of approving gemtuzumab ozogamicin combination therapy for treatment of acute myeloid leukemia. |
|
FDA Panel Recommends Approval of CAR T-Cell Therapy for Pediatric ALL The Oncologic Drug Advisory Committee voted in favor of approving tisagenlecleucel for the treatment of pediatric acute lymphocytic leukemia, making it the first chimeric antigen receptor T-cell therapy recommended for approval. |
|
On Location: Fostamatinib Improves Platelet Counts in Certain Patients With Heavily Pretreated ITP Results from two phase III studies showed that fostamatinib appeared to improve platelet counts in patients with heavily pretreated severe chronic immune thrombocytopenia. Look for more coverage of the European Hematology Association’s 22nd Congress in our August issue! |
This is (supposed to be) a reflective diary by a (not very) anonymous biomedical scientist who works somewhere in the south of England. One day this diary may well be submitted to the Health and Care Professions Council as evidence of ongoing continual professional development....
26 July 2017 (Wednesday) - ASH Update
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment